Retatrutide and Tirzepatide are reshaping medical weight-loss conversations. Tirzepatide targets two hormone pathways, while Retatrutide is studied for triple-pathway signaling. Their comparison highlights a shift toward biology-based weight management, emphasizing physician-guided care for safe, effective metabolic treatment.